Table 2. Cox regression analysis of survival in SCLC.
| Variables | Unadjusted | Adjusted | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| OS | |||||
| Chemotherapy | 0.36 (0.21–0.62) | <0.001 | 0.45 (0.24–0.85) | 0.01 | |
| Smoking index | 1.0010 (1.0004–1.0016) | <0.001 | 1.0011 (1.0004–1.0018) | 0.002 | |
| PCI | 0.24 (0.07–0.77) | 0.02 | 0.32 (0.10–1.05) | 0.06 | |
| Age | 1.03 (1.00–1.06) | 0.02 | 1.01 (0.97–1.04) | 0.65 | |
| Stage III | 2.06 (1.06–4.00) | 0.03 | 1.82 (0.63–5.29) | 0.27 | |
| N+ | 1.84 (1.05–3.23) | 0.03 | 1.50 (0.64–3.49) | 0.35 | |
| DFS | |||||
| N+ | 2.16 (1.27–3.67) | 0.004 | 1.97 (1.16–3.36) | 0.01 | |
| Neoadjuvant chemotherapy | 0.37 (0.18–0.79) | 0.01 | 0.44 (0.21–0.94) | 0.03 | |
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; N, node; OS, overall survival; PCI, prophylactic cranial irradiation; SCLC, small-cell lung cancer.